Literature DB >> 3133872

Comparative immune responses to native cell envelope antigens and the hot sodium dodecyl sulfate insoluble fraction (PG) of Brucella abortus in cattle and mice.

A J Winter1, G E Rowe.   

Abstract

Brucella abortus vaccines composed of native cell envelopes or outer membrane proteins of smooth strain 2308 were compared with a vaccine (PG) composed of the insoluble residue of strain 2308 cell envelopes which had been extracted with hot sodium dodecyl sulfate. Vaccines were given by injection in an oil base adjuvant containing trehalose dimycolate and muramyl dipeptide or without adjuvant. Mice vaccinated with 30 micrograms native cell envelopes or PG and challenged 4 weeks later with virulent B. abortus strain 2308 displayed equivalent levels of protective immunity at 1 and 4 weeks post-infection. Heifers were vaccinated with 5 mg of antigens in adjuvant; PG was also administered without adjuvant. Humoral and cell mediated immune (CMI) responses were tested at monthly intervals. PG without adjuvant induced negligible immune responses. Native cell envelope antigens induced significantly higher titers of whole cell agglutinins over a 3-month period than did PG, although revaccination with PG in adjuvant enhanced the production of agglutinins and both vaccines induced antibodies to the O polysaccharide. Lymphocyte blastogenesis responses and delayed hypersensitivity reactions to porin and group 3 proteins were stimulated by both native and PG vaccines, and the magnitude of the responses did not differ significantly between the treatment groups. These vaccines were therefore comparable in their capacity to induce protective immunity in mice and CMI responses in cattle, whereas antibody responses induced by PG in cattle were generally lower. These findings provide a basis for evaluation of nonliving B. abortus vaccines in cattle.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3133872     DOI: 10.1016/0165-2427(88)90057-8

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  8 in total

1.  Antigens of Brucella abortus S19 immunodominant for bovine lymphocytes as identified by one- and two-dimensional cellular immunoblotting.

Authors:  B M Brooks-Worrell; G A Splitter
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

2.  Sodium dodecyl sulfate- and salt-extracted antigens from various Brucella species induce proliferation of bovine lymphocytes.

Authors:  B M Brooks-Worrell; G A Splitter
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

3.  Capacity of passively administered antibody to prevent establishment of Brucella abortus infection in mice.

Authors:  A J Winter; J R Duncan; C G Santisteban; J T Douglas; L G Adams
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

4.  Cloning, nucleotide sequence, and expression of the Brucella melitensis omp31 gene coding for an immunogenic major outer membrane protein.

Authors:  N Vizcaíno; A Cloeckaert; M S Zygmunt; G Dubray
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

5.  Effectiveness of natural and synthetic complexes of porin and O polysaccharide as vaccines against Brucella abortus in mice.

Authors:  A J Winter; G E Rowe; J R Duncan; M J Eis; J Widom; B Ganem; B Morein
Journal:  Infect Immun       Date:  1988-11       Impact factor: 3.441

6.  Alteration of protective and serologic responses in BALB/c mice vaccinated with chemically modified versus nonmodified proteins of Brucella abortus 19.

Authors:  G W Pugh; L B Tabatabai
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

7.  Variation of Brucella abortus 2308 infection in BALB/c mice induced by prior vaccination with salt-extractable periplasmic proteins from Brucella abortus 19.

Authors:  G W Pugh; L B Tabatabai
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

Review 8.  A history of the development of Brucella vaccines.

Authors:  Eric Daniel Avila-Calderón; Ahidé Lopez-Merino; Nammalwar Sriranganathan; Stephen M Boyle; Araceli Contreras-Rodríguez
Journal:  Biomed Res Int       Date:  2013-06-03       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.